3 July 2017 07:00 BST

AstraZeneca announced today that it has completed* the previously-communicated agreement with Recordati S.p.A (Recordati) for the commercial rights to Seloken/Seloken ZOK (metoprolol tartrate and metoprolol succinate, respectively) and associated Logimax fixed-dose combination (metoprolol succinate and felodipine) medicines in Europe. Metoprolol succinate is a beta-blocker for the control of hypertension, angina and heart failure.

Based on the limited level of ongoing interest that AstraZeneca will retain in the medicines in Europe, the upfront and tiered royalty payments received from Recordati will be reported as Other Operating Income in the Company's financial statements. An upfront payment of $290 million will be accounted for in the second quarter of 2017.

*With the exception of Romania, which is subject to separate closing.

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas - Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit and follow us on Twitter @AstraZeneca.

Media Relations           
Esra Erkal-Paler  UK/Global  +44 203 749 5638 
Karen Birmingham    UK/Global    +44 203 749 5634   
Rob Skelding    UK/Global    +44 203 749 5821   
Jacob Lund    Sweden    +46 8 553 260 20   
Michele Meixell    US    +1 302 885 2677   
Investor Relations
Thomas Kudsk Larsen   +44 203 749 5712 
Craig Marks  Finance, Fixed Income, M&A +44 7881 615 764 
Henry Wheeler  Oncology +44 203 749 5797 
Mitchell Chan  Oncology +1 240 477 3771 
Lindsey Trickett  Cardiovascular & Metabolic Diseases +1 240 543 7970 
Nick Stone  Respiratory +44 203 749 5716 
Christer Gruvris Autoimmunity,   Neuroscience & Infection +44 203 749 5711
US toll free +1 866 381 7277

This information is provided by RNS
The company news service from the London Stock Exchange


About Us

AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialisation of prescription medicines. As a leader in gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease medicines, AstraZeneca generated global revenues of US $32.8 billion in 2009. For more information please visit:


Documents & Links